Business
PRTC's Seaport Appoints Seasoned Execs to Team
PRTC's Seaport Appoints Seasoned Execs to Team.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n \n18 June 2024\nPureTech Health plc\n \nPureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team\n \nAntony Loebel, M.D., CNS drug development expert and former CEO and CMO at Sunovion Pharmaceuticals, appointed as Seaport's Chief Medical Officer and President of Clinical Development\n \nLana Gladstein, J.D., experienced attorney across all legal matters, including corporate governance, M&A transactions, alliance management and intellectual property, joins Seaport as General Counsel\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced it has expanded its executive team with the appointment of Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D., as General Counsel.\n \nDr. Loebel was most recently the President and Chief Executive Officer of Sunovion Pharmaceuticals, a global pharmaceutical company focused on CNS drug development and commercialization, from 2019 to 2023. He served as the company's Chief Medical Officer from 2011 to 2019. Dr. Loebel was instrumental in the growth of Sunovion from a small to mid-size company with over $2.5 billion in net revenue. He played a key role in the development and commercialization of LATUDA® for the treatment of patients with bipolar depression and schizophrenia, with the product achieving commercial success in the U.S. and globally under his leadership. Other products developed and approved under Dr. Loebel's leadership included APTIOM® for partial-onset seizures and KYNMOBI® for the treatment of \"OFF\" episodes in patients with Parkinson's disease. Prior to Sunovion, Dr. Loebel's industry experience included drug development and medical affairs roles at Dainippon Sumitomo Pharma America and Pfizer, Inc. A board-certified psychiatrist, Dr. Loebel is a Fellow of the American College of Neuropsychopharmacology and a Life Fellow of the American Psychiatric Association. He has received multiple recognitions and awards including the International Society of CNS Drug Development's 20th Anniversary Award for a co...